Evidence map›Paper›PMID 41885448›Full record

ReviewJournal of enzyme inhibition and medicinal chemistry2026

PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators.

Sunny Periyasamy, Thyla Jarrett, Joe Truong, Rachid Skouta

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sunny PeriyasamyDepartment of Chemistry, University of Massachusetts, Amherst, MA, USA.
Thyla JarrettDepartment of Chemistry, University of Massachusetts, Amherst, MA, USA.
Joe TruongDepartment of Chemistry, University of Massachusetts, Amherst, MA, USA.
Rachid SkoutaDepartment of Chemistry, University of Massachusetts, Amherst, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The degradation of overexpressed proteins has emerged as a promising strategy for halting disease progression, particularly in cancer. Traditional small-molecule drugs often face limitations in the elimination of pathogenic proteins, leading to the development of targeted protein degradation (TPD) approaches. A prominent strategy for TPD is the proteolysis targeting chimaera (PROTAC) which harnesses the ubiquitin proteasome system, the cell's innate degradation machinery, to degrade proteins of interest (POIs). In this review, we will focus on the design and synthetic strategies that led the advancements of PROTACs as a cancer therapy for the targeted degradation of poly ADP-ribose polymerases (PARPs), glutathione peroxidase 4 (GPX4) and epigenetic regulators. We also aim to address the prevailing challenges in PROTAC development and clinical translation, namely target diversification, oral bioavailability, stability, degradation efficiency, and optimising multivalent binding.

Indexed as

Antineoplastic AgentsEpigenesis, GeneticNeoplasmsPhospholipid Hydroperoxide Glutathione PeroxidasePoly(ADP-ribose) PolymerasesHumansMolecular StructureProteolysisProteolysis Targeting ChimeraAntineoplastic AgentsPhospholipid Hydroperoxide Glutathione PeroxidasePoly(ADP-ribose) PolymerasesProteolysis Targeting ChimeraChemical synthesis of anticancer compoundsepigenetic regulatorsGPX4proteolysis targeting chimaera (PROTAC)targeted protein degradation (TPD)

Identifiers

PMID41885448
PMCPMC13084866

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.